U.S. markets open in 7 hours 2 minutes
  • S&P Futures

    4,204.00
    -19.00 (-0.45%)
     
  • Dow Futures

    33,855.00
    -162.00 (-0.48%)
     
  • Nasdaq Futures

    13,897.75
    -83.50 (-0.60%)
     
  • Russell 2000 Futures

    2,297.70
    -12.40 (-0.54%)
     
  • Crude Oil

    71.80
    -0.35 (-0.49%)
     
  • Gold

    1,814.40
    -47.00 (-2.52%)
     
  • Silver

    27.04
    -0.77 (-2.78%)
     
  • EUR/USD

    1.1998
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.5690
    0.0000 (0.00%)
     
  • Vix

    18.15
    +1.13 (+6.64%)
     
  • GBP/USD

    1.3991
    +0.0004 (+0.03%)
     
  • USD/JPY

    110.6900
    +0.0770 (+0.07%)
     
  • BTC-USD

    39,144.66
    -1,334.37 (-3.30%)
     
  • CMC Crypto 200

    971.89
    -20.59 (-2.07%)
     
  • FTSE 100

    7,184.95
    +12.47 (+0.17%)
     
  • Nikkei 225

    29,018.33
    -272.68 (-0.93%)
     

Do Insiders Own Lots Of Shares In Nymox Pharmaceutical Corporation (NASDAQ:NYMX)?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

The big shareholder groups in Nymox Pharmaceutical Corporation (NASDAQ:NYMX) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people." So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.

With a market capitalization of US$194m, Nymox Pharmaceutical is a small cap stock, so it might not be well known by many institutional investors. In the chart below, we can see that institutional investors have bought into the company. We can zoom in on the different ownership groups, to learn more about Nymox Pharmaceutical.

See our latest analysis for Nymox Pharmaceutical

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Nymox Pharmaceutical?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in Nymox Pharmaceutical. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Nymox Pharmaceutical's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

We note that hedge funds don't have a meaningful investment in Nymox Pharmaceutical. With a 39% stake, CEO Paul Averback is the largest shareholder. In comparison, the second and third largest shareholders hold about 4.5% and 2.4% of the stock.

Looking at the shareholder registry, we can see that 50% of the ownership is controlled by the top 16 shareholders, meaning that no single shareholder has a majority interest in the ownership.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.

Insider Ownership Of Nymox Pharmaceutical

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own a reasonable proportion of Nymox Pharmaceutical Corporation. Insiders own US$87m worth of shares in the US$194m company. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.

General Public Ownership

The general public, with a 48% stake in the company, will not easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Nymox Pharmaceutical better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with Nymox Pharmaceutical (at least 2 which are potentially serious) , and understanding them should be part of your investment process.

Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.